Policy | September 10, 2024
Atal Innovation Mission, NITI Aayog hosts 20th MedTech Mitra Technical advisory meeting
MedTech Mitra initiative aims to empower MedTech innovators and advance healthcare solutions
MedTech Mitra initiative aims to empower MedTech innovators and advance healthcare solutions
Ordspono is Regeneron’s first approved bispecific antibody and will provide an off-the-shelf option that can be administered in the out-patient setting, with hope for complete remission
CN201 is a next generation CD3xCD19 bispecific antibody that augments and diversifies Merck’s pipeline, with potential applications in B-cell malignancies and autoimmune diseases
Approval is based on data from two Phase III studies in branch and central retinal vein occlusion (RVO) showing early and sustained vision improvements non-inferior to aflibercept
Reported profit after tax declined 19% year-on-year to Rs 76 crores
Vabysmo PFS is the first and only syringe prefilled with an FDA-approved bispecific antibody to treat retinal conditions that can cause blindness
The consultative meet, a first of its kind, will bring together representatives from diverse domains of Traditional Medicine (TM) in India
Detailed data from Phase 3 ECHELON-3 study demonstrate investigational ADCETRIS regimen reduced risk of death by 37 percent compared to chemotherapy alone
Merck shared updates on the company’s oncology pipeline and focused R&D approach
Third Phase 3 trial in third type of lymphoma to show improvement in overall survival with an ADCETRIS-containing regimen
Subscribe To Our Newsletter & Stay Updated
